article thumbnail

Methods of Commercializing Intellectual Property – Part I

Intepat

Introduction Intellectual Property refers to those intangible assets which are created by virtue of the human intellect. The various forms of intellectual property are already well known- trademarks, patents, copyrights, industrial designs, trade secrets, domain names and geographical indications.

article thumbnail

SEC Continues to Police Confidentiality Provisions for Theoretical Whistleblower Suppression

LexBlog IP

Morgan Securities, LLC (“JPMS”) for allegedly including overbroad release provisions in settlement agreements. ” Another SEC official also commented that “[t]hose drafting or using confidentiality agreements need to ensure that they do not include provisions that impede potential whistleblowers.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Role of Arbitration In Intellectual Property

Biswajit Sarkar Copyright Blog

Intellectual property rights are becoming increasingly globally and economically oriented. There has been discussion over the extent and specific restrictions of some intellectual property rights’ arbitrability. Arbitration in Intellectual Property. In Booz Allen and Hamilton Inc. SBI Home Finance Ltd.

article thumbnail

NLRB to Release Memo Clarifying Impact of McLaren Macombs on Confidentiality and Non-Disparagement Restrictions

LexBlog IP

The Board sent shockwaves through employment law in its February 21, 2023, decision in McLaren Macomb , which held that simply offering a draft settlement agreement with broad confidentiality and non-disparagement provisions violated the National Labor Relations Act (“NLRA”). Are those impacted by this decision?

article thumbnail

Celltrion Stelara (Ustekinumab) Settlement With J&J

LexBlog IP

It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S. market on March 7, 2025, if approved by FDA.

article thumbnail

NDA: An Effective Way to Protect Confidential Information

LexBlog IP

A settlement agreement was reached where Elation could inspect the software developed by Shi and prevent the use of any trade secrets or confidential information. The jury also found Shi breached the settlement agreement. Elation could then reinspect the software both before and after the first sale of the product by Shi.

article thumbnail

Formycon/Fresenius Kabi and Samsung Bioepis Settlements with J&J and Janssen Biotech regarding Ustekinumab

LexBlog IP

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J. Economic terms of the settlement were not disclosed in the press release.